GSK's First Quarter Financial Highlights

GSK plc has announced a notable 2% increase in its first-quarter turnover for 2023, reaching £6.95 billion compared to the same period in 2024. When adjusted for constant exchange rates, the growth escalates to 4%.

Earnings and Profit Surge

The company witnessed a remarkable 55% year-on-year surge in total earnings per share (EPS) to 39.7 pence, with core EPS also seeing a 4% rise to 44.9 pence. Operating profit experienced a significant 49% jump to £2.2 billion from the first quarter of 2024, and the adjusted operating profit increased by 4% to £2.5 billion.

Strategic Progress and Future Outlook

CEO Emma Walmsley emphasized GSK's strong progress, showcasing the quality and resilience of its portfolio. The Specialty Medicines division, GSK's largest business, contributed significantly to sales. The company has also made strides in R&D, securing two out of five anticipated FDA product approvals this year and acquiring a promising new oncology asset. GSK is now focusing on upcoming launches and pivotal trials for potential new medicines across various therapeutic areas.